BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36005563)

  • 1. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications.
    Nilsson C; Linde F; Hulegårdh E; Garelius H; Lazarevic V; Antunovic P; Cammenga J; Deneberg S; Eriksson A; Jädersten M; Björkvall CK; Möllgård L; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
    Haematologica; 2023 Apr; 108(4):1015-1025. PubMed ID: 36005563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal Abnormalities and Prognosis in
    Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
    J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
    Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
    Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
    Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
    Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort.
    Marshall RC; Tlagadi A; Bronze M; Kana V; Naidoo S; Wiggill TM; Carmona SC
    Int J Lab Hematol; 2014 Dec; 36(6):656-64. PubMed ID: 24666762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
    Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
    Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
    Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
    Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
    Elrhman HAEA; El-Meligui YM; Elalawi SM
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
    Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.
    Suzuki R; Onizuka M; Kojima M; Shimada M; Okamura K; Fukagawa S; Tsuboi K; Kikuchi A; Kobayashi H; Shintani A; Ogawa Y; Kawada H; Hotta T; Ando K
    Int J Hematol; 2007 Dec; 86(5):422-8. PubMed ID: 18192111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Canaani J; Labopin M; Huang XJ; Arcese W; Ciceri F; Blaise D; Irrera G; Corral LL; Bruno B; Santarone S; Van Lint MT; Vitek A; Esteve J; Mohty M; Nagler A
    Am J Hematol; 2018 Jun; 93(6):736-744. PubMed ID: 29498106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
    Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
    Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.